Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
Naveen Reddy, Pramod Reddy, Nedyalka Staykova, Anastas Batalov et al.
Citations
1 citations
Journal
Arthritis Research & Therapy
Topics
Biosimilars and Bioanalytical Methods
Field-Weighted Citation Impact (FWCI)
0.24
article
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
Lithuanian University of Health Sciences (LT), Dr. Reddy's Laboratories (United States) (US), Plovdiv University (BG), Medical University Plovdiv (BG), Northwest Hospital (US), Dr. Reddy's Laboratories (India) (IN)